OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Jain on Advances With Surgery and Systemic Therapy in CRC With Liver Metastases

October 7th 2021

Shikha Jain, MD, FACP, discusses advances with surgical interventions and systemic therapies in colorectal cancer with liver metastases.

Dr. Hansen on the PFS Benefit With Ide-Cel in Relapsed/Refractory MM

October 7th 2021

Doris Hansen, MD, discusses the progression-free survival benefit yielded by idecabtagene vicleucel on the phase 2 KarMMa trial in patients with pretreated relapsed/refractory multiple myeloma.

Dr. Anderson on the Methods Utilized in the KarMMa Trial in Multiple Myeloma

October 6th 2021

Larry Anderson, MD, PhD, discusses the methods utilized in the phase 2 KarMMa trial in multiple myeloma.

Dr. Harbeck on the Background of the WSG ADAPT-TP Trial in HR+, HER2+ Breast Cancer

October 6th 2021

Nadia Harbeck, MD, PhD, discusses the background of the phase 2 WSG ADAPT-TP trial in hormone receptor-positive, HER2-positive early-stage breast cancer.

Dr. Castaneda Puglianini on Outcomes With Cilta-Cel in Relapsed/Refractory Myeloma

October 6th 2021

Omar Castaneda Puglianini, MD, discusses results from the phase 1b/2 CARTITUDE-1 trial evaluating ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Dr. Agarwal on Adverse Effects With Belzutifan and Mitigation Strategies in RCC

October 6th 2021

Neeraj Agarwal, MD, discusses the adverse effects associated with belzutifan in patients with renal cell carcinoma.

Dr. O’Malley on the Rationale to Evaluate Balstilimab/Zalifrelimab in Cervical Cancer

October 6th 2021

David M. O'Malley, MD, discusses the rationale to evaluate the combination of balstilimab and zalifrelimab in cervical cancer.

Dr. Chatzkel on the Emergence of Novel Therapies in Metastatic Urothelial Cancer

October 6th 2021

Jonathan A. Chatzkel, MD, discusses the emergence of novel therapies in relapsed/refractory locally advanced or metastatic urothelial cancer.

Dr. Mansfield Discusses Ongoing Trials With Chemoimmunotherapy in Mesothelioma

October 6th 2021

Aaron S. Mansfield, MD, discusses ongoing trials with chemoimmunotherapy in mesothelioma.

Dr. Burris on the Integration of Sacituzumab Govitecan in Metastatic TNBC

October 5th 2021

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the integration of sacituzumab govitecan-hziy into the treatment landscape of metastatic triple-negative breast cancer.

Dr. Patel on the Role of CTLA-4 Inhibitors in NSCLC

October 5th 2021

Manish Patel, DO, discusses the role of CTLA-4 inhibitors in non–small cell lung cancer.

Dr. Girard on Real-World PFS Data With Durvalumab in NSCLC

October 5th 2021

Nicolas Girard, MD, discusses the progression-free survival data with durvalumab observed in a real-world analysis of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer.

Dr. Colombo on Practice-Changing KEYNOTE-826 Data in Metastatic Cervical Cancer

October 5th 2021

Nicoletta Colombo, MD, PhD, discusses efficacy achieved with the addition of pembrolizumab to chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer.

Dr. Baz on the Role of Alkylating Agents in Relapsed/Refractory Multiple Myeloma

October 5th 2021

Rachid Baz, MD, discusses the role of alkylating agents in relapsed/refractory multiple myeloma.

Dr. Naumann on the Evolution of Immunotherapy in Endometrial Cancer

October 5th 2021

R. Wendel Naumann, MD, discusses the evolution of immunotherapy in endometrial cancer.

Dr. Brown on the Clinical Implications of the PRIMA Trial in Ovarian Cancer

October 5th 2021

Jubilee Brown, MD, discusses the clinical implications of the phase 3 PRIMA trial in advanced ovarian cancer.

Dr. Nassif on the Efficacy of Early-Phase Clinical Trials in Soft Tissue Sarcoma

October 4th 2021

Elise Nassif, MD, discusses the efficacy of early-phase clinical trials in soft tissue sarcoma.

Dr. Rimawi on Mitigating Interstitial Lung Disease in HER2+ Breast Cancer

October 4th 2021

Mothaffar Fahed Rimawi, MD, discusses mitigating interstitial lung disease/pneumonitis in HER2-positive breast cancer.

Dr. Hamilton on the Potential Integration of Novel SERDs in ER+/HER2- Breast Cancer

October 4th 2021

Erika P. Hamilton, MD, discusses the potential integration of novel selective estrogen receptor degraders into the treatment armamentarium for ER-positive, HER2-negative breast cancer.

Dr. Vose on the Use of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

October 4th 2021

Julie M. Vose, MD, MBA, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma.